Search

everythinglearnresearchcommunity

for

Search:↓

The herbal supplement improved hair growth, density, and strength without side effects.

PRP shows promise for treating mild alopecia areata but needs more research for cicatricial alopecias.

Alopecia areata severity is linked to increased TH1 and TH2 activity.

PPAR-γ agonists like pioglitazone may help manage lichen planopilaris but don't fully reverse scarring.

Children with atopic diseases have a higher risk of developing alopecia areata.

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

PCA patients have more harmful bacteria and antibiotic resistance, needing specific testing for treatment.

QR678 Neo® improved seborrheic dermatitis symptoms in a small group of patients.

Certain gene variants can influence acne risk and severity.

Higher miR-34a levels and the A variant of the MIR-34A gene are linked to increased risk and severity of alopecia areata.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Elevated granulysin levels may indicate disease activity in vitiligo and alopecia areata.

Regulatory γδ T cells help protect hair follicles from alopecia areata and promote hair regrowth.

A specific group of immune and skin cells may cause chronic inflammation in atopic dermatitis.

Hidradenitis Suppurativa has genetic links, with certain gene mutations more common in patients and a third of cases having a family history.

Fibroblast changes in systemic sclerosis may help understand disease severity and treatment.

Alopecia areata patients show unique protein activity patterns, suggesting imbalanced signaling pathways.

TNFα, IFNγ, and Substance P significantly affect prolactin levels in human skin, suggesting new treatments for skin and hair conditions.

IL-1 family cytokines are crucial for skin defense and healing, but their imbalance can cause skin diseases.

The immune processes causing VKH and vitiligo are similar in dogs and humans.

SOCS3 treatment can prevent hair loss by stopping harmful immune responses.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.

EGCG may help treat alopecia areata by blocking certain immune responses and reducing specific harmful immune cells.

New imaging technologies improve skin diagnosis but face cost and training challenges.

T-regulatory cells are important for skin health and can affect hair growth and reduce skin inflammation.

Specific immune cells and pathways contribute to hair follicle inflammation and hair loss, suggesting potential treatments for lichen planopilaris.

Botulinum toxin shows promise for treating scalp sweating but not for hair growth.

Type 2 diabetes slows down skin and hair renewal by blocking important stem cell activation in mice.

Alopecia areata patients show increased inflammation and OX40 activation, suggesting a new treatment target.

Different types of hair loss have unique cellular changes, suggesting new treatment targets.